Response to highly active antiretroviral therapy according to duration of HIV infection

被引:0
作者
Pezzotti, P
Pappagallo, M
Phillips, PN
Boros, S
Valdarchi, C
Sinicco, A
Zaccarelli, M
Rezza, G
机构
[1] Ist Super Sanita, Reparto AIDS & MST, I-00161 Rome, Italy
[2] UCL Royal Free & Univ Coll Med Sch, London, England
[3] Univ Turin, Turin, Italy
[4] IRCCS L Spallanzani, Rome, Italy
关键词
antiretroviral therapy; HIV seroconverters; effectiveness; cohort study;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate whether duration of HIV-1 infection influences the response to highly active antiretroviral therapy (HAART). Design: Prospective study of individuals (Italian Seroconversion Study cohort) with well-estimated dates of HIV-1 seroconversion. Methods: This analysis included 277 participants who began HAART (defined as three antiretroviral drugs used in combination). Cox regression models were used to evaluate the association between duration of infection (as categorical variable [less than or equal to3, 3-7.5, >7.5 years from seroconversion] or continuous variable) and an immunologic (rise in CD4 count >100 cells/mm(3)) and a virologic (decline in plasma HIV-RNA to unquantifiable levels) outcome. All analyses were stratified by center of recruitment and adjustment, when used, was for gender, age at inception of HAART, injection drug use. previous antiretroviral therapy, lag-time between positive and negative HIV test result, year of starting HAART, clinical stage, CD4 count, and HIV-RNA at time of HAART. Results: HAART was initiated a median of 6.4 years after seroconversion, There was a median follow-up of 1.6 years after starting HAART to the calendar cut-off (November 1999). One-hundred-eighty-one (65.3%) patients experienced a decline in viral load to below quantifiable levels and 184 (66.4%) experienced a rise in CD4 >100 cells/mm(3). In the Cox models, by 1-year increase in duration of infection, we estimated a lower crude hazard of achieving a CD4 count increase >100 cells (relative hazard [RH], 0.96: 95% confidence interval [CI]. 0.92-1.01; p = .09), and a lower hazard of reaching an unquantifiable level of plasma HIV-RNA (RH, 0.97; 95%CI, 0.93-1.02; p = .20). After adjustment, these values became 0.99 (95%CI, 0.93-1.04; p = .62) and 0.98 (95%CI, 0.93-1.03; p = .48), respectively. When duration of HIV infection was considered as a categorical variable, the results were consistent with those already described. Conclusions: These results suggest that the duration of HIV infection does not seem to play an important independent role in determining the virologic and immunologic responses to HAART.
引用
收藏
页码:473 / 479
页数:7
相关论文
共 30 条
  • [1] [Anonymous], 1992, AIDS, V6, P421
  • [2] [Anonymous], MMWR RECOMM REP
  • [3] BHIVA Writing Committee, 2000, HIV Med, V1, P76
  • [4] Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
    Carpenter, CCJ
    Cooper, DA
    Fischl, MA
    Gatell, JM
    Gazzard, BG
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schechter, M
    Schooley, RT
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03): : 381 - 390
  • [5] Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01): : 78 - 86
  • [6] CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration, 2000, HIV Med, V1, P224
  • [7] HIV infection induces changes in CD4(+) T-cell phenotype and depletions within the CD4(+) T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
    Connors, M
    Kovacs, JA
    Krevat, S
    GeaBanacloche, JC
    Sneller, MC
    Flanigan, M
    Metcalf, JA
    Walker, RE
    Falloon, J
    Baseler, M
    Stevens, R
    Feuerstein, I
    Masur, H
    Lane, HC
    [J]. NATURE MEDICINE, 1997, 3 (05) : 533 - 540
  • [8] Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: Estimates of the population effect of treatment
    Dorrucci, M
    Balducci, M
    Pezzotti, P
    Sinicco, A
    Alberici, F
    Rezza, G
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 22 (01): : 65 - 70
  • [9] Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
    Egger, M
    Hirschel, B
    Francioli, P
    Sudre, P
    Wirz, M
    Flepp, M
    Rickenbach, M
    Malinverni, R
    Vernazza, P
    Battegay, M
    Bernasconi, E
    Burgisser, P
    Erb, P
    Fierz, W
    Grob, P
    Gruninger, U
    Jeannerod, L
    Ledergerber, B
    Luthy, R
    Matter, L
    Opravil, M
    Paccaud, F
    Perrin, L
    Pichler, W
    Piffaretti, GC
    Rutschmann, O
    Zanetti, G
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117): : 1194 - 1199
  • [10] Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
    Gorochov, G
    Neumann, AU
    Kereveur, A
    Parizot, C
    Li, TS
    Katlama, C
    Karmochkine, M
    Raguin, G
    Autran, B
    Debré, P
    [J]. NATURE MEDICINE, 1998, 4 (02) : 215 - 221